Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men*
- 12 January 1996
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 59 (1) , 72-82
- https://doi.org/10.1016/s0009-9236(96)90026-0
Abstract
This double-blind, placebo-controlled crossover study was designed to differentiate the pharmacodynamic effects of the angiotensin II receptor antagonist losartan from the angiotensin converting enzyme inhibitor enalapril. Effects of placebo, enalapril (10 mg), and losartan (20 and 100 mg) on local venous and systemic pressor responses to angiotensin I and II were compared in eight healthy male subjects. Treatments were administered orally approximately 4 hours before agonist infusions into a dorsal hand vein. Local changes in hand vein diameter and systemic blood pressure were monitored during the infusions. The 100 mg dose of losartan attenuated local venoconstrictor and systemic pressor responses to angiotensin I and II. In contrast, enalapril blocked only responses to angiotensin I. Both losartan and enalapril increased plasma renin concentration compared with placebo. These results are consistent with direct antagonism of angiotensin II receptors by losartan and with indirect effects of enalapril through inhibition of angiotensin converting enzyme.Keywords
This publication has 16 references indexed in Scilit:
- Comparison of Angiotensin-Converting Enzyme Inhibition with Angiotensin II Receptor Antagonism in the Human ForearmJournal of Cardiovascular Pharmacology, 1993
- Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.Hypertension, 1993
- Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.British Journal of Clinical Pharmacology, 1993
- Pharmacology of Nonpeptide Angiotensin II Receptor AntagonistsAnnual Review of Pharmacology and Toxicology, 1992
- Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.Circulation, 1991
- 109. Efficacy and safety of oral MK-954 (DuP 753), an angiotensin receptor antagonist, in essential hypertensionJournal Of Hypertension, 1991
- The effect of oral cilazapril and prazosin on the constrictor effects of locally infused angiotensin I and noradrenaline in human dorsal hand veins.British Journal of Clinical Pharmacology, 1989
- Influence of Carvedilol on the Responsiveness of Human Hand Veins to Noradrenaline and DinoprostDrugs, 1988
- Hemodynamic Responses to Angiotensin I in Normal Volunteers and the Antagonism by the Angiotensin-Converting Enzyme Inhibitor CilazaprilJournal of Cardiovascular Pharmacology, 1987
- EnalaprilDrugs, 1986